Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
Purpose ::: Aurora A kinase is critical in assembly and function of the mitotic spindle. It is overexpressed in various tumor types and implicated in oncogenesis and tumor progression. This trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of MLN8054, a selective small-molecule inhibitor of Aurora A kinase.
The present invention relates to vectors useful for the administration of active principles (PA), preferably medicinal or nutritional, especially orally or parenterally. The technical problem solved by the invention is that consisting in the supply of vectors formed by (nano) or (micro) particles based on polyamino acids, and which are inert with respect to PA (proteins), of controllable granulometry, resistant and economical. The invention has an average particle size of less than 200 mum and consists of a polyamino acid of the Leu / Glu type, in which Leu / Glu + Leu> = 20% and Mw> = 10,000 D.